METHODS FOR TREATING AND PREVENTING C. DIFFICILE INFECTION
Methods of treating or preventing a C. difficile infection and the associated pathological conditions related to C. difficile infection, are disclosed.
1 . A method of treating C. difficile infection in a subject in need thereof, the method comprising administering to said subject an effective amount of a compound, or a salt thereof, wherein the compound is compound A′ having the following structural formula:
such that said C. difficile infection in said subject is treated.
2 . The method of claim 1 , wherein said C. difficile infection is a recurrent C. difficile infection.
3 . The method of claim 1 , wherein said compound is administered in combination with at least one or more additional therapy used for treating C. difficile infection.
4 . The method of claim 3 , wherein said additional therapy comprises administering an antibiotic, a probiotic or a fecal transplant.
5 . The method of claim 4 , wherein said antibiotic is metronidazole or vancomycin.
6 - 7 . (canceled)
8 . A method of treating a bacterial infection without causing C. difficile infection in a subject who is at risk of developing a C. difficile infection, said method comprising administering to said subject an effective amount of a compound, or a salt thereof, wherein said compound is compound A′ having the following structural formula:
such that said bacterial infection in said subject is treated without causing C. difficile infection.
9 . A method of treating a bacterial infection without substantially disrupting gut microbiome in a subject who is at risk of developing a C. difficile infection, said method comprising administering to said subject an effective amount of a compound, or a salt thereof, wherein said compound is compound A′ having the following structural formula:
such that said bacterial infection in said subject is treated without substantially disrupting gut microbiome.
10 . The method of claim 9 , wherein treating bacterial infection without substantially disrupting gut microbiome does not result in a C. difficile infection in said subject.
11 . The method of claim 1 , further comprising, prior to administering, selecting a subject at risk of developing a C. difficile infection.
12 . A method of treating a bacterial infection in a subject who is predisposed to developing a C. difficile infection, said method comprising administering to said subject an effective amount of a compound, or a salt thereof, wherein said compound is compound A′ having the following structural formula:
such that said bacterial infection in said subject is treated.
13 . A method of treating a bacterial infection in a subject who is at risk of developing C. difficile infection, said method comprising the steps of:
selecting a subject at risk of developing a C. difficile infection; and
administering to said subject an effective amount of a compound, wherein the compound is compound A′, or a salt thereof, having the following structural formula:
such that said bacterial infection in said subject is treated.
14 - 19 . (canceled)
20 . The method of claim 1 , wherein said compound is Compound A having the following structural formula:
21 . The method of claim 8 , wherein the subject at risk of developing C. difficile infection is a subject selected from the group consisting of: a subject who was recently treated with one or more antibiotic; a subject who has had surgery of the gastrointestinal tract; a subject who has a disease of the colon; a subject who has a weakened immune system; a subject who is on chemotherapy; a subject who previously had a C. difficile infection; a subject who is 65 years or older; a subject who has a kidney disease; a subject who takes proton-pump inhibitors; and a subject who is living in an environment that predisposes said subject to developing a C. difficile infection.
22 . The method of claim 21 , wherein said antibiotic was a broad spectrum antibiotic.
23 - 24 . (canceled)
25 . The method of claim 21 , wherein said disease of the colon is an inflammatory bowel disease or colorectal cancer.
26 - 32 . (canceled)
33 . The method of claim 21 , wherein said environment comprises a hospital, a nursing home or an assisted living facility.
34 - 35 . (canceled)
36 . The method of claim 1 , wherein said compound is administered orally or intravenously.
37 - 45 . (canceled)
46 . The method of claim 9 , wherein the subject at risk of developing C. difficile infection is a subject selected from the group consisting of: a subject who was recently treated with one or more antibiotic; a subject who has had surgery of the gastrointestinal tract; a subject who has a disease of the colon; a subject who has a weakened immune system; a subject who is on chemotherapy; a subject who previously had a C. difficile infection; a subject who is 65 years or older; a subject who has a kidney disease; a subject who takes proton-pump inhibitors; and a subject who is living in an environment that predisposes said subject to developing a C. difficile infection.
47 . The method of claim 13 , wherein the subject at risk of developing C. difficile infection is a subject selected from the group consisting of: a subject who was recently treated with one or more antibiotic; a subject who has had surgery of the gastrointestinal tract; a subject who has a disease of the colon; a subject who has a weakened immune system; a subject who is on chemotherapy; a subject who previously had a C. difficile infection; a subject who is 65 years or older; a subject who has a kidney disease; a subject who takes proton-pump inhibitors; and a subject who is living in an environment that predisposes said subject to developing a C. difficile infection.